A microcarrier-based bioreactor offers many advantages in growing human mesenchymal stem cells. For example, hMSCs secrete high amounts of extracellular matrix, which enhances their adhesion on ...

Microcarrier Market Poised to Reach US$ 4.07 Billion by 2032 with Robust CAGR of 8.87% - Vaccine Manufacturing and Therapeutics, Investments in Biopharmaceutical R&D - ResearchAndMarkets.com.

Jeroen Verheyen, Co-Founder & CEO, Semarion, said: “We are delighted to open the Early Adopter Programme for our SemaCyte Microcarrier Platform to researchers working in drug discovery.

A single-use, stirred tank bioreactor process from MilliporeSigma allows for scalable, cell-based production of viral vaccines, and avoids the drawbacks of egg-based production.

Researchers developed a novel microcarrier for large-scale cell production and expansion that offers higher yield and cost-effectiveness compared to traditional methods, and reduces steps required ...

The partnership will integrate SPT Labtech’s firefly ® liquid handling platform with Semarion’s SemaCyte ® microcarrier technology to develop a flexible, scalable, and automated workflow ...

Researchers from Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a novel microcarrier for large-scale cell production and expansion that ...

The partnership will integrate SPT Labtech’s firefly ® liquid handling platform with Semarion’s SemaCyte ® microcarrier technology to develop a flexible, scalable, and automated workflow ...